期刊
PET/CT APPLICATIONS IN NON-NEOPLASTIC CONDITIONS
卷 1228, 期 -, 页码 81-92出版社
BLACKWELL SCIENCE PUBL
DOI: 10.1111/j.1749-6632.2011.06015.x
关键词
PET/CT; dementia; Alzheimer's disease
资金
- NIA NIH HHS [AG032554, R01 AG035137, AG035137, R01 AG013616, R21 AG032554] Funding Source: Medline
- NATIONAL INSTITUTE ON AGING [R21AG032554, R01AG035137, R01AG013616] Funding Source: NIH RePORTER
Clinical use of positron emission tomography (PET) is now well established in neurodegenerative disorders, especially in the diagnosis of dementia. Measurement of cerebral glucose metabolism is of significant value, and it facilitates early diagnosis, appropriate differential diagnosis, and the evaluation of drug treatment in patients with dementia. In addition, tracers offer new perspectives for studying the neuropathology of underlying dementia, such as the accumulation of amyloid proteins, tau-proteins, or the presence of neuroinflammation. Finally, PET tracer studies of different neurotransmitter systems in dementia may not only increase the understanding of pathophysiologic mechanisms of the different disorders, but also improve diagnostic accuracy. In conclusion, PET imaging with different tracers offers reliable biomarkers in dementia, which can assist clinicians in the diagnosis of different dementing disorders, especially in the situation of overlapping phenotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据